Skip to main content
Menu

Posts tagged with "Clinical Trials"

  • Clinical Trials

    CureVac Comes Up Short

    I wasn’t planning on having this turn into Coronavirus Vaccine Week again around here, but we do have some news. Yesterday afternoon CureVac, the German mRNA vaccine company, reported results of their Phase III trial in 40,000 patients around the world. They weren’t good. And the data that have come out today don’t make things… Read More
  • Clinical Trials

    Ivermectin As a COVID-19 Therapy

    I last wrote about ivermectin here, but I’m getting so many question about it that I need to revisit the topic. Although (I’ve said this before), I believe that I will regret doing it, because I expect the signal/noise in the comments section to degenerate to mid-pandemic levels in response. The mechanistic story here has… Read More
  • Clinical Trials

    Treatment With MDMA

    A theme that I return to every so often on the blog is the degree to which we don’t understand the molecular mechanisms of psychiatric syndromes. I’ve found that many people outside of the biomedical world are surprised by this – depression, for example, is something that’s distinctive enough, widespread enough, and certainl… Read More
  • Clinical Trials

    Moderna’s Upcoming Clinical Trials

    One of the ways in which this pandemic will be looked back on as a pivot point will (almost certainly) be in the use of mRNA vaccines. It seems clear at this point that these have come through spectacularly against the coronavirus: every new study of their effects in the broad population just adds to… Read More
  • Clinical Trials

    Merck Keeps Plowing On

    I last wrote about the small-molecule antiviral molnupiravir here, and we finally have more information from Merck and Ridgeback about its effects in clinical trials. An interim analysis of the Phase II data from trials in both outpatients and in hospitalized coronavirus patients has been completed, and the news is. . .mixed. In the outpatient… Read More
  • Clinical Trials

    Oligonucleotides And Their Discontents

    I remember being at a chemistry meeting in New Jersey back in around 1990 or 1991, where a speaker mentioned in passing that most of the people in the room would probably soon be offered a chance to move to California and work for some small company trying to develop antisense drugs. There was a… Read More
  • Clinical Trials

    AstraZeneca’s US Vaccine Trial Data

    Update: this has turned into a stupid, needless, mess. Which frankly seems to be AstraZeneca’s pandemic brand so far. It turns out that the company’s press release (as discussed below) is apparently more of an interim read than reflective of the final data. The NIH took the extraordinary step of stating its concerns about this… Read More
  • AI and Machine Learning

    AI and Drug Discovery: Attacking the Right Problems

    I’ve been meaning to write some more about artificial intelligence, machine learning, and drug discovery, and this paper (open access) by Andreas Bender is an excellent starting point. I’m going to be talking in fairly general terms here, but for practitioners in the field, I can recommend this review of the 2020 literature by Pat Walt… Read More
  • Clinical Trials

    The Problem with COVID-19 Clinical Trials

    Let’s talk about a painful subject. I am of the opinion – and I’m far from alone – that the most reliable way to determine if a possible therapy has any usefulness is a randomized, double-blinded controlled clinical trial. I can be a bit more specific than that, even: let’s make that “a trial that… Read More
  • Alzheimer's Disease

    Lilly’s Alzheimer’s Data

    That’s a post title that I could have used eight or ten times over the lifetime of this blog – Eli Lilly has been hammering away at Alzheimer’s for a long time now. They have yet another anti-amyloid antibody study out this week, and (as has happened over and over in this area) it as… Read More